Hey everyone! 👋

Ive been following and researching about psilocybin and it's mental health benefits. And liking what I've been seeing so far.

I have been interested in buying some stock in the industry for a little while now and I have little extra cash to play with so felt ready to pull the trigger. I've been reading on here, Google and using AI to help research the best course of action and Gemini suggestions PSIL over buying in individual companies like ATAI, CMPS and MNMD.

So I'm curious what's the advantage and disadvantages to buying PSIL?

What's the advantage or disadvantages to buying in individual stocks?

Any words or wisdom or advice would be greatly appreciated.

Much thanks 😊

Eagerly waiting for next phase of durability data to come out. Thinking about what I might do with various outcomes. What are you doing?

I’m looking to diverse my portfolio and add a bit of shroom stocks to that. What would be some good options to look into? Thanks.

Big jump at 1:40 pm today from Atai and Compass. No news... What's the deal? Insiders making moves?

Lykos Therapeutics' MDMA application was declined by the FDA in August 2024. After the April 2026 executive order, the resubmission is now eligible for a Priority Voucher. Here is what actually changed and the realistic path to approval.

Missed DFTX weeks ago.

Looking back, I'm wondering what I should have noticed earlier.

For those who caught it, what gave you conviction before the Phase 3 results?

Did you expect this outcome, or was it just another catalyst you happened to be watching?

Like I feel this was Obvious, and real asymmetric bet, like just comparing with CMPS I can see the momentum was going well.

https://preview.redd.it/2z08n3698eah1.png?width=1088&format=png&auto=webp&s=893788c496c8bd1dc3eb1d474cf0e0eb863fbd5e

https://preview.redd.it/aalb4tk98eah1.png?width=862&format=png&auto=webp&s=20e036d9bbb6e51e3827c413ec7a53176fb82c86

What are your expectations for the MADRS difference for the upcoming 26-week durability readout?

View Poll

This thread is for questions and general discussion relating to the psychedelics industry. The weekly thread will refresh every Monday morning before stock market open.

Two weeks ago there was a thread, talking about this yet it hasn't received enough attention in my eyes.

May there be a chain reaction coming out of this? For the broad public a lawsuit describing the side effects of under supervised 5-meo dosing could be detrimental.

What is there to consider? Minor dip, crash on a broader market scale, maybe even a new subgroup of legislators/politicians opposing psychedelic therapies based on *insert age-old arguments and appeals to authority".?

GHRS has been printing good data, but its such a dice roll betting on 5-MeO-DMT.

Thursday and Friday were great days for all of us owning stocks in CMPS, ATAI and HELP. Is it reasonable to believe they will fall back on monday? Will you sell and buy at the dip?

Dftx up another 20% after dilution with 5m volume. Cmps not moving as much yet part B around the corner. Help up after public offering.

Am i missing something ?

DFTX ran huge on positive trials, compass is kind of their biggest competitor and one of the OG’s but doesn’t have nearly the buzz around it right now.

For anyone saying the results of DT120 are on par with anything, you're talking out of your ...

The results are unprecedented, this is head-to-head:

Auvelity's pivotal GEMINI trial showed a 3.8-point placebo-adjusted MADRS improvement at Week 6 and 2.2-point separation at Week 1.

DT120 reported:

• 14.2-point placebo-adjusted improvement at Week 1
• 8.1-point placebo-adjusted improvement at Week 6
• 7.3-point placebo-adjusted improvement at Week 12

Those numbers are dramatically larger. Based solely on effect size, DT120's antidepressant signal is roughly 2–4 times larger than Auvelity's.

Comp360 (not completely comparable because TRD) but someone mentioned DFTX saw similar results in TRD so make of that what you will:

Using the same style as the Auvelity comparison:

COMP360's best publicly reported studies showed approximately:

• 6–7 point placebo-adjusted MADRS improvement at peak
• 4–6 point placebo-adjusted separation around Week 6
• 2–4 point separation by Week 12

DT120 reported:

• 14.2-point placebo-adjusted improvement at Week 1
• 8.1-point placebo-adjusted improvement at Week 6
• 7.3-point placebo-adjusted improvement at Week 12

So less difference but still meaningful

This is why the stock is up because investors are finally waking up to what we knew all along...

For reference Axsome today is trading at 12.6 billion market cap.

Also stop remission rates for a single dose to a daily pill.